RxDoctor Payments Data

Cheri Coyle, MD

Obstetrics & Gynecology · Newport News, VANPI 1992712277

Payments from drug & device makers

$3,295in general payments, 2019–2025

Across 163 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$776
  • Sumitomo Pharma America, Inc.$393
  • Amgen$326
  • Myovant Sciences Inc.$198
  • AbbVie$180
  • Daiichi Sankyo Inc.$167
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,05293%
  • Education$2437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,295 in reported general payments places this provider in the 85th percentile of 992 obstetrics & gynecology providers in Virginia.

See all obstetrics & gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$57,357
Medicare patients
241
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron17$11,769
Estradiol138$10,766
GemtesaVibegron11$8,791
PremarinEstrogens, Conjugated12$6,210
Clobetasol Propionate24$2,547
Estradiol (Twice Weekly)Estradiol13$1,535
ValacyclovirValacyclovir Hcl30$1,268
Risedronate Sodium13$1,083
Ibandronate Sodium26$918
Terconazole12$265
Alendronate Sodium22$258
Bupropion XlBupropion Hcl15$182
Fluconazole31$143
Venlafaxine Hcl ErVenlafaxine Hcl12$71
Triamcinolone Acetonide14$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$776$11,76917 claims
Sumitomo Pharma America, Inc.Gemtesa$393$8,79111 claims
PfizerPremarin$156$6,21012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 992 obstetrics & gynecology providers in Virginia.

Other obstetrics & gynecology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →